A large number of pharmaceutical companies such as Tofflon and Buchang Pharma issued favorable announcements

 In a blink of an eye, February 2022 has passed, and March is quietly approaching.
On this occasion, a large number of pharmaceutical companies, such as Buchang Pharmaceutical, Yifan Pharmaceutical, Tonghua Dongbao, and Tofflon, actively issued announcements and announced new dynamic
.
Buchang Pharmaceutical's Wholly-owned Subsidiary Obtained a Notice of Approval for Drug Clinical Trials On March 1, Buchang Pharmaceutical issued an announcement that Shandong Danhong Pharmaceutical Co.
, Ltd.
(referred to as "Shandong Danhong"), a wholly-owned subsidiary of Shandong Buchang Pharmaceutical Co.
, Ltd.
Recently, I received the "Drug Clinical Trial Approval Notice" approved and issued by the State Drug Administration for BC0306 capsules
.
BC0306 capsules are mainly used for the treatment of non-alcoholic steatohepatitis, and there are currently no drugs with the same target on the market at home and abroad
.
As of the disclosure date of this announcement, the research and development expenses invested by the company in the BC0306 project were approximately RMB 28.
2288 million
.
Yifan Pharmaceutical Holding Subsidiary Signs Exclusive License Agreement On March 1, Yifan Pharmaceutical issued an announcement that Singapore Yiyi, a holding subsidiary of the company, agreed to license the exclusive distribution rights of the research product F-627 in Germany to APOGEPHA.
In order to obtain exclusive sales rights in the cooperation area, APOGEPHA needs to pay Singapore Yiyi a non-refundable upfront payment of US$400,000, development milestone payments up to US$1,000,000 and sales milestone payments up to US$37,500,000
.
Tonghua Dongbao's triple-target inhibitor product (THDBH101) completed the enrollment of subjects in China Phase I clinical trial The SGLT1/SGLT2/DPP4 triple-target inhibitor product THDBH101 Capsules (formerly known as WXSHC071 Capsules) developed by (Hangzhou) Biopharmaceutical Co.
, Ltd.
(“Dongbao Zixing”) has been approved by the State Drug Administration for clinical trials.
After the approval, the Phase I clinical trial in China has been launched, and the first patient enrollment has been successfully completed recently
.
HDBH101 Capsule is an innovative small-molecule oral SGLT1/SGLT2/DPP4 triple-target inhibitor entering clinical trial stage
.
On the basis of the classical and mature mechanism of action of SGLT2, the drug further enhances the hypoglycemic effect through the synergistic effect of SGLT1 and DPP4, and uses the effect of SGLT1 in regulating glucose absorption in the intestine to further enhance the hypoglycemic effect, and at the same time introduces a more stable and lasting inhibitory effect on DPP4 in the body The hypoglycemic effect of various mechanisms plays a role of superimposing effect
.
As of the date of this announcement, the company has invested approximately RMB 36.
71 million in research and development in this project
.
Tofflon plans to raise no more than 3.
2 billion yuan to increase the size of the pharmaceutical equipment field.
Tofflon released a fixed increase plan on the evening of February 28.
The company plans to issue no more than 189 million shares (including this number) to specific objects.
The total amount of funds raised will not be More than 3.
2 billion yuan (inclusive)
.
According to the fixed increase plan, after deducting the issuance costs, 530 million yuan will be used for the biopharmaceutical equipment industry trial production center project, 990 million yuan will be used for the Jiangsu biomedical equipment industrialization base project, and 1.
25 billion yuan will be used for the Hangzhou life science industrialization base project.
430 million yuan is used to supplement working capital
.
Zhongsheng Pharmaceutical's holding subsidiary, ZSP1273, a first-class innovative drug, received the US FDA's drug clinical trial approval notice.
Zhongsheng Pharmaceutical issued an announcement on February 28.
Recently, Guangdong Zhongsheng Ruichuang Biotechnology Co.
, Ltd.
"Zhongsheng Ruichuang") Class I innovative drug ZSP1273 received the Study May Proceed Letter (Study May Proceed Letter) issued by the U.
S.
Food and Drug Administration ("FDA"), agreeing to conduct clinical trials in the United States for ZSP1273
.
ZSP1273 is a kind of innovative drug with a clear mechanism of action and independent intellectual property rights developed by Zhongsheng Ruichuang for major sudden infectious diseases - influenza A and human avian influenza
.
Simcere Pharma's SIM0408 Drug Clinical Trial Approved On February 28, Simcere Pharma and Germany's Vivoryon Therapeutics jointly announced that SIM0408, a new Alzheimer's disease drug under development jointly developed by the two parties in China, has been reviewed by the State Drug Administration.
Center approved to enter clinical trials in China
.
It is reported that SIM0408 is an oral small molecule inhibitor of glutaminyl cyclase (QPCT), and is undergoing Phase IIb clinical research in Europe
.
By inhibiting QPCT and thus preventing the formation of the toxic N3pE amyloid, SIM0408 may act early in the disease, potentially preventing neuronal damage
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.